Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.

One of the biggest impacts of the new administration could be in stem cell research, according to Laura Cadden. Support for the use of embryonic stem cells would open a whole world of opportunity for specialist biotech firms. Laura picks 5 small-cap biotech stocks that would make huge gains on new stem cell legislation.